Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FDA's Dermatologic and Ophthalmic Drugs advisory committee gave a favorable panel review for an NDA from the companies for Macugen
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury